Rgenta Therapeutics

Rgenta Therapeutics is a clinical-stage biopharmaceutical company developing oral, small-molecule RNA-targeting medicines focused on oncology and neurological disorders. The company applies a proprietary platform that uses genomic data to identify high-impact RNA target sites, then selects molecules from specialized compound libraries designed to engage those sites and RNA-binding regulatory proteins. By modulating RNA function with high specificity, Rgenta aims to prevent the production of disease-associated proteins and unlock therapies for previously 'undruggable' targets. Its lead program, RGT-61159, is advancing through clinical trials.